Physician profile
Lamia Dris
NPI 1295990224
$7,557.51
in general payments reported to CMS, 2019-2025
19 companies · $1,260 in 2025
The $1,260 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,662 · 2020: $82.23 · 2021: $242 · 2022: $412 · 2023: $649 · 2024: $1,250 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Travel and Lodging: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.51 |
| Travel and Lodging | $324.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,594.54 | 2019-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Boston Scientific Corporation | $919.48 | 2019-2024 | Emblem Mri S-Icd |
| Medtronic, INC. | $772.33 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Biosense Webster, INC. | $615.04 | 2019-2025 | Carto 3 |
| Medtronic Vascular, INC. | $427.05 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $259.77 | 2024-2025 | Assure Wcd |
| Cardiva Medical, INC. | $224.89 | 2021-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Ensoetm, Optowire |
| Amgen INC. | $167.96 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $144.80 | 2023-2024 | Camzyos |
| Pfizer INC. | $109.75 | 2019 | |
| Medical Device Business Services, INC. | $82.49 | 2019 | |
| Edwards Lifesciences Corporation | $44.69 | 2023 | Pascal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.74 | 2021-2025 | Lifevest |
| Cleerly, INC. | $36.79 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Merck Sharp & Dohme LLC | $33.12 | 2025 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $27.73 | 2025 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $22.07 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $16.16 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamia Dris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.